600572.SH
康恩贝
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.21
−2.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.7B | 6.5B | 6.5B | 6.7B | 6.0B |
| Cost of Revenue | 3.1B | 3.0B | 3.1B | 2.8B | 2.4B |
| Gross Profit | 3.6B | 3.5B | 3.5B | 3.9B | 3.6B |
| Operating Expenses | |||||
| R&D Expense | 259.4M | 262.2M | 300.0M | 298.1M | 195.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 549.3M | 541.7M | 564.5M | 545.8M | 519.9M |
| Selling & Marketing Expense | 2.1B | 2.0B | 1.9B | 2.3B | 2.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.0B | 2.9B | 2.8B | 3.2B | 2.8B |
| Cost and Expenses | 6.1B | 5.9B | 5.9B | 6.0B | 5.3B |
| Operating Income (EBIT) | 693.6M | 673.2M | 798.9M | 788.3M | 602.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 669.3M | 645.2M | 779.9M | 767.7M | 590.0M |
| Income Tax Expense | 167.7M | 153.6M | 121.6M | 93.0M | 129.9M |
| Bottom Line | |||||
| Net Income | 483.4M | 474.4M | 622.4M | 591.6M | 358.1M |
| Earnings from Cont. Ops | 501.6M | 491.6M | 658.4M | 674.7M | 460.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 483.4M | 474.4M | 622.4M | 591.6M | 358.1M |
| Per Share | |||||
| Basic EPS | CN¥0.19 | CN¥0.19 | CN¥0.25 | CN¥0.23 | CN¥0.14 |
| Diluted EPS | CN¥0.19 | CN¥0.19 | CN¥0.25 | CN¥0.23 | CN¥0.14 |
| Revenue Per Share | CN¥2.63 | CN¥2.59 | CN¥2.62 | CN¥2.62 | CN¥2.35 |
| Shares | |||||
| Basic Shares Outstanding | 2.5B | 2.5B | 2.5B | 2.6B | 2.6B |
| Diluted Shares Outstanding | 2.5B | 2.5B | 2.5B | 2.6B | 2.6B |
| Profitability Metrics | |||||
| EBITDA | — | 1.0B | 1.1B | 1.1B | 884.8M |
| D&A | — | 350.3M | 350.0M | 327.4M | 282.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026